Sibylla Biotech is a preclinical stage company focused on developing small molecule degraders to find new therapeutics for unmet medical needs. The technology is powered by computer simulations and AI methods and is applicable to various therapeutic areas.

Sibylla Biotech

Domain Not Resolving

Person Schema

CrUX Dataset

Gravatar Profiles

CrUX Top 50m

Choopa

Constant Hosting

Engineering

Serena Bonifati

Ward Capoen

Ciro Spedaliere

Marianne Bjordal

Bruno Montanari

Sonia Poli

Chief Scientific Officer

European Union (EU) Biotechnology Companies

Biotechnology Companies with Early Stage Venture Funding

Pharmaceutical Companies With Less Than $10M in Revenue (Top 10K)

Health Care Companies With Fewer Than 1000 Employees (Top 10K)

Sibylla Biotech developed small molecule folding interfering degraders (FIDs) that can address a range of therapeutic areas.

V-Bio Ventures

Series A - Sibylla Biotech

Computer and Software Products and Electrical and Scientific Products

Trento

Trentino-Alto Adige

Italy

Europe

Sibylla and MD Anderson team up on small-molecule protein degraders

Sibylla Biotech and MD Anderson Announce Strategic Collaboration to Discover and Develop Small-Molecule Protein Degraders

Sibylla Biotech and MD Anderson Agree to Jointly Discover and Develop Small-Molecule Protein Degraders

Growing admirers for Sibylla's tech targeting 'paradigm shift in drug design'

Sibylla Biotech and MD Anderson Announce Strategic Collaboration to Discover and Develop Small-Molecule Protein ...

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Sep 28, 2024 5:31 PM	f247366f
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Sep 28, 2024 5:31 PM	46d2c269
crunchbase trigger	general	Nov 11, 2024 10:30 AM	4abc88d5
crunchbase profile	general	Nov 12, 2024 8:57 AM	43d5a172
li profile	general
translate crunchbase fundingrounds	general	Nov 12, 2024 9:45 AM	d7a931c7
peers	general	Sep 28, 2024 5:31 PM	47abec7f
news basic	general	Sep 28, 2024 5:31 PM	97d377b2
bundesanzeiger	filings
financials download nd	financials
private financials	financials

IT:SIBYLLABIOTECH

Sibylla Biotech